TGFBI: A novel therapeutic target for cancer

Int Immunopharmacol. 2024 Jun 15:134:112180. doi: 10.1016/j.intimp.2024.112180. Epub 2024 May 10.


TGFBI, an extracellular matrix protein induced by transforming growth factor β, has been found to exhibit aberrant expression in various types of cancer. TGFBI plays a crucial role in tumor cell proliferation, angiogenesis, and apoptosis. It also facilitates invasion and metastasis in various types of cancer, including colon, head and neck squamous, renal, and prostate cancers. TGFBI, a prominent p-EMT marker, strongly correlates with lymph node metastasis. TGFBI demonstrates immunosuppressive effects within the tumor immune microenvironment. Targeted therapy directed at TGFBI shows promise as a potential strategy to combat cancer. Hence, a comprehensive review was conducted to examine the impact of TGFBI on various aspects of tumor biology, including cell proliferation, angiogenesis, invasion, metastasis, apoptosis, and the immune microenvironment. This review also delved into the underlying biochemical mechanisms to enhance our understanding of the research advancements related to TGFBI in the context of tumors.

Keywords: Cancer; Immune microenvironment; Metastasis; TGFBI.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Apoptosis / drug effects
  • Cell Proliferation / drug effects
  • Extracellular Matrix Proteins / metabolism
  • Humans
  • Molecular Targeted Therapy
  • Neoplasms* / drug therapy
  • Neoplasms* / immunology
  • Neoplasms* / metabolism
  • Neovascularization, Pathologic / drug therapy
  • Neovascularization, Pathologic / immunology
  • Transforming Growth Factor beta* / metabolism
  • Tumor Microenvironment* / drug effects
  • Tumor Microenvironment* / immunology


  • Transforming Growth Factor beta
  • Extracellular Matrix Proteins
  • Antineoplastic Agents